Literature DB >> 31027915

Satisfactory analgesia with minimal emesis in day surgeries: a randomised controlled trial of morphine versus hydromorphone.

H Shanthanna1, J Paul2, P Lovrics3, T Vanniyasingam2, P J Devereaux4, M Bhandari5, L Thabane4.   

Abstract

BACKGROUND: Opioids remain the mainstay therapy for post-surgical pain. Although both morphine and hydromorphone are potent analgesics, it has been suggested that hydromorphone is clinically better. Our primary objective was to compare morphine with hydromorphone for achieving satisfactory analgesia with minimal emesis (SAME).
METHODS: We performed a multicentre RCT in 402 patients having ambulatory surgery. A random computer-generated allocation, stratified by site, was developed by our pharmacy. Concealment was achieved by allocating patients to study groups by nurses using sequentially coded study medication syringes having equi-analgesic doses, made available in the postoperative recovery room. Patients, health providers, and research personnel were blinded. The operating-room protocol allowed for routine anaesthetic management, excluding the use of study medications. Study medications were administered by recovery nurses as per an algorithm. Analyses utilised the intention-to-treat principle, and regression analyses were used for outcomes as appropriate and using multiple imputation.
RESULTS: Of 751 patients, 402 were randomised between morphine (n=199) and hydromorphone (n=203). Baseline and intraoperative variables were comparable across the groups. The odds of achieving SAME were similar between the groups (odds ratio: 1.01; 95% confidence interval: 0.57-1.80). There were no differences in the side-effects of severe itching, respiratory depression, or sedation. Patient satisfaction, discharge times, and post-discharge outcomes, including pain and nausea/vomiting over 24 h, were also comparable.
CONCLUSIONS: There was no difference between morphine and hydromorphone regarding analgesia and common side-effects. The appearance of dose-limiting side-effects is idiosyncratic; the clinical decision must be based on individual responses. CLINICAL TRIAL REGISTRATION: NCT02223377. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ambulatory surgery; analgesics; hydromorphone; morphine; opioid; postoperative nausea and vomiting; side-effects

Mesh:

Substances:

Year:  2019        PMID: 31027915     DOI: 10.1016/j.bja.2019.03.036

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  The effect of ultrasound-guided erector spinae plane block on postsurgical pain: a meta-analysis of randomized controlled trials.

Authors:  Mark C Kendall; Lucas Alves; Lauren L Traill; Gildasio S De Oliveira
Journal:  BMC Anesthesiol       Date:  2020-05-01       Impact factor: 2.217

2.  Analgesic Efficacy of Preemptive Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Colorectal Cancer Surgery.

Authors:  Kwan Young Hong; Duk Kyung Kim; Hue Jung Park; Woo Seog Sim; Won Gook Wi; Woo Yong Lee; Hee Cheol Kim; Jin Young Lee
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

3.  Hydromorphone Protects against CO2 Pneumoperitoneum-Induced Lung Injury via Heme Oxygenase-1-Regulated Mitochondrial Dynamics.

Authors:  Jia Shi; Shi-Han Du; Jian-Bo Yu; Yan-Fang Zhang; Si-Meng He; Shu-An Dong; Yuan Zhang; Li-Li Wu; Cui Li; Hai-Bo Li
Journal:  Oxid Med Cell Longev       Date:  2021-04-09       Impact factor: 6.543

4.  Machine learning for infection risk prediction in postoperative patients with non-mechanical ventilation and intravenous neurotargeted drugs.

Authors:  Yi Du; Haipeng Shi; Xiaojing Yang; Weidong Wu
Journal:  Front Neurol       Date:  2022-08-01       Impact factor: 4.086

5.  Patient-controlled intravenous analgesia with opioids after thoracoscopic lung surgery: a randomized clinical trial.

Authors:  Hong Yu; Wei Tian; Zhao Xu; Rongjuan Jiang; Liang Jin; Wenjie Mao; Ying Chen; Hai Yu
Journal:  BMC Anesthesiol       Date:  2022-08-08       Impact factor: 2.376

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.